Document is current
Any future updates will be listed below
-
Authors
Hørsdal, Oskar Kjærgaard https://orcid.org/0000-0003-1009-3768
Frederiksen, Peter Hartmund https://orcid.org/0000-0003-3712-7980
Helgestad, Ole Kristian Lerche https://orcid.org/0000-0003-3847-8758
Ravn, Hanne Berg https://orcid.org/0000-0003-4702-5195
Møller, Jacob Eifer https://orcid.org/0000-0003-2873-5845
Wiggers, Henrik https://orcid.org/0000-0002-9753-4142
Nielsen, Roni Ranghøj https://orcid.org/0000-0001-9228-3869
Gopalasingam, Nigopan https://orcid.org/0009-0006-6363-7406
Berg-Hansen, Kristoffer https://orcid.org/0000-0002-5110-0656
-
Funding
Funding for this research was provided by:
Aase og Ejnar Danielsens Fond
Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond
The Royal Danish Library, Aarhus University
Aarhus Universitet
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 12 June 2025
First Online: 24 June 2025
Declarations
:
: The protocol for this study was pre-planned and included in the same ethical approval granted by the Danish National Animal Experiment Inspectorate (Permit no: 2023–15-0201–01466, issued on 19/06–2023). The treatment and ethical oversight of the animals strictly followed established welfare protocols and regulatory standards as mandated by both Danish and European legislation. All methodologies and animal handling procedures were in full compliance with the EU Directive 2010/63/EU on the protection of animals used for scientific purposes.
: Not applicable.
: Not applicable.
: Henrik Wiggers has been the principal or a sub-investigator in studies involving the following pharmaceutical companies: Merck, Pfizer Ltd., Bayer Healthcare AG, Astra Zeneca A/S, Sanofi Aventis, MSD Denmark, Novartis Healthcare A/S, Boehringer Ingelheim, Amgen, Merck Sharp & Dohme Ltd., Novo Nordisk, Eli Lilly. The remaining authors declare no conflict of interests.
